Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.

The investigation into human butyrylcholinesterase (BChE) inhibitors as therapeutic agents for Alzheimer's disease (AD) holds significant promise, addressing both symptomatic relief and disease progression. In the pursuit of novel drug candidates with a selective BChE inhibition pattern, we focused on naturally occurring template structures, specifically Amaryllidaceae alkaloids of the carltonine-type. Herein, we explored a series of compounds implementing an innovative chemical scaffold built on the 3- and 4-benzyloxy-benzylamino chemotype. Notably, compounds 28 (BChE IC = 0.171 ± 0.063 μM) and 33 (BChE IC = 0.167 ± 0.018 μM) emerged as top-ranked BChE inhibitors. simulations elucidated the binding modes of these compounds within BChE. CNS availability was predicted using the BBB score algorithm, corroborated by permeability assessments with the most potent derivatives. Compound 33 was also inspected for aqueous solubility, microsomal and plasma stability. Chemoinformatics analysis validated these BChE inhibitors for oral administration, indicating favorable gastrointestinal absorption in compliance with Lipinski's and Veber's rules. Safety assessments, crucial for the chronic administration typical in AD treatment, were conducted through cytotoxicity testing on human neuroblastoma (SH-SY5Y) and hepatocellular carcinoma (HepG2) cell lines.